From Lead Asset to Expandable Therapeutic Pipeline
11Three is building a portfolio of transdermal therapeutic assets powered by the SENDS™ delivery platform, beginning with RELIEFTA™ and expanding into selected pain, CNS, hormone, and regenerative applications.
Localized Transdermal Delivery
Designed to support sustained delivery of selected active compounds through the skin.
Extended Wear Architecture
Built around a high-conformance patch system designed for prolonged application.
RELIEFTA™ — Lead Transdermal Asset
RELIEFTA™ is 11Three’s lead SENDS™-enabled transdermal asset, built around a
250 mg active-layer architecture designed for extended localized delivery.
A Platform-Enabled Lead Asset
Defined Active-Layer Architecture
A meticulously controlled 250 mg formulation, combining lidocaine, WS-12, terpenes, SENDS™, and a high-conformance polymer base for optimal delivery.
Extended Wear Design
Engineered with a high-conformance adhesive system, RELIEFTA™ ensures prolonged transdermal application, enhancing patient experience.
Commercial Development Path
Designed to connect formulation, cGMP manufacturing, regulatory pathways, and clinic commercialization within a scalable development model.
Active-Layer Composition
Lidocaine Base USP
5.0% — 12.50 mg
WS-12
3.0% — 7.50 mg
Beta-Caryophyllene
1.0% — 2.50 mg
Myrcene
0.5% — 1.25 mg
Linalool
0.5% — 1.25 mg
SENDS™ Carrier Base
1.0% — 2.50 mg
Proprietary Polymer Base
89.0% — 222.50 mg
Total Active Layer
250 mg
Localized transdermal delivery
Cooling sensate support
Terpene-Enhanced Formulation
Extended 24–48 hour wear architecture
Commercial Development Path
Integration with manufacturing and regulatory infrastructure
Point-of-care commercialization
Strategic partnerships
Pipeline Opportunities
Non-Opioid Pain & Neuropathic
CNS & Hormone Applications
Regenerative & Peptide Opportunities
Development Targets
Pipeline Opportunities
Development Targets
Ketamine HCl, Gabapentin, Pregabalin
Diclofenac, Bupivacaine
CRPS, Chronic neuropathic pain
Post-operative pain
Ketorolac, Testosterone, Estradiol
Target Areas
Progesterone, Melatonin Complex
Post-operative pain, Endocrine optimization
Sleep-related applications
BPC-157, GHK-Cu
NAD+ / NMN, CJC-1295
Regenerative Applications
Tissue repair, Cellular support
Inflammatory applications
Development Targets
Pipeline Opportunities
Strategic Development
SENDS™ Technology Process
Our innovative process ensures precise delivery and efficacy.
1
Formulation Science
Developing the optimal transdermal formulation using SENDS™ technology.
2
Manufacturing Excellence
Ensuring cGMP manufacturing standards for quality and safety.
3
Regulatory Pathway
Navigating FDA and NDC requirements for market readiness.
11Three's Vision
Revolutionizing Transdermal Therapeutics
At 11Three Tech, we are committed to transforming the landscape of transdermal therapeutics through our pioneering SENDS™ technology. Our lead asset, RELIEFTA™, exemplifies our dedication to innovation and excellence in drug delivery systems. By leveraging advanced formulation science and strategic partnerships, we aim to expand our therapeutic pipeline and deliver impactful solutions to patients worldwide. Join us as we pave the way for the next generation of pharmaceutical advancements.